Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS Texas Cardiac Biomarker Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - TexasPolicy RPLAB046

    Biomarkers for Myocardial Infarction and Chronic Heart Failure

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Texas Policy RPLAB046 alerts

    Get alerted when Policy RPLAB046 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This reimbursement policy establishes laboratory management criteria for cardiac biomarkers used in evaluating acute coronary syndrome, myocardial infarction, dyspnea, and chronic heart failure. Requirements may vary by product and are subject to plan documents, provider contracts, coding rules, and claim review.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure
    Policy CodePolicy RPLAB046
    Change TypeAdministrative/reference updateno reimbursement change
    Effective DateDec 4, 202615d
    Next Review DateN/A
    Key ActionBill quantitative troponin only in an appropriate outpatient facility and no more than four times within the first 72 hours when acute coronary syndrome criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 document update revised the policy references while leaving reimbursement information unchanged.

    A November 7, 2025 update included a literature review and changes to the Reimbursement Information section.

    4Maximum quantitative troponin measurements in first 72 hours

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4/yearMaximum outpatient BNP or NT-proBNP measurements per year for chronic heart failure severity
    Not reimbursableQualitative outpatient cardiac troponin
    Not reimbursableOutpatient ST2 analysis
    Unchanged2026 reimbursement information

    Cardiac Biomarker Coverage Criteria

    Quantitative Troponin for Acute Coronary Syndrome

    Quantitative cardiac troponin testing may be reimbursable when ALL of the following criteria are met:

    ALL of the following

    • Individual presents with signs and symptoms of acute coronary syndrome (see NOTE 1).
    • Quantitative measurement of cardiac troponin T or I is performed for the diagnosis of myocardial infarction (MI).
    • Testing is performed at an outpatient facility capable of performing an adequate clinical MI evaluation.

      Testing performed in an independent laboratory or physician's office that is not capable of an adequate clinical MI evaluation is not reimbursable.

    • Testing occurs within the first 72 hours following initial presentation.Up to 4 tests within 72 hours

    BNP or NT-proBNP Indications

    BNP or NT-proBNP measurement may be reimbursable when ANY of the following indications applies:

    ANY of the following

    • Measurement of B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) to diagnose heart failure in an individual presenting with dyspnea.
    • Measurement of BNP or NT-proBNP to establish disease severity in an individual with chronic heart failure.Up to 4 times per year in the outpatient setting

    Nonreimbursable Cardiac Biomarker Testing

    The following cardiac biomarker testing is not reimbursable in the specified circumstances:

    ANY of the following

    • For an individual presenting with signs and symptoms of acute coronary syndrome (see NOTE 1), measurement of aspartate aminotransferase (AST/SGOT), cardiac creatine kinase isoenzyme MB (CK-MB), creatine kinase (CK), creatine kinase isoenzymes, lactate dehydrogenase (LD/LDH), or myoglobin for the diagnosis and/or prognosis of MI.
    • For an individual presenting with signs and symptoms of acute coronary syndrome (see NOTE 1), cardiac biomarker measurement in an outpatient setting that is not capable of performing an adequate clinical MI evaluation, including an independent laboratory or physician's office.
    • In the outpatient setting, qualitative measurement of cardiac troponin T or I.
    • For an individual presenting with signs and symptoms of acute coronary syndrome (see NOTE 1), measurement of copeptin, troponin C, C-reactive protein, heart-type fatty acid binding protein (H-FABP), or any other cardiac biomarker not listed above for the diagnosis and/or prognosis of MI.

    Coding and Frequency Limits

    Legacy or alternative myocardial infarction biomarkers not reimbursable for acute coronary syndrome evaluationCPTNot Covered
    82550Assay of CK (CPK)
    82552Assay of CPK in blood
    82553Creatine MB fraction
    82554Creatine isoforms
    83615Lactate (LD) (LDH) enzyme
    83625Assay of LDH enzymes
    83874Assay of myoglobin
    84450Transferase (AST) (SGOT)
    86140C-reactive protein
    86141C-reactive protein, high sensitivity
    Potentially reimbursable quantitative troponin and natriuretic peptide testing subject to clinical, setting, and frequency criteriaCPTCovered
    83880Assay of natriuretic peptide
    84484Assay of troponin, quantitative
    Codes associated with qualitative troponin, ST2 or other biomarker testing subject to nonreimbursement rulesCPTNot Covered
    84512Assay of troponin, qualitative
    83006Growth stimulation gene 2
    82725Assay of blood fatty acids
    84999Unlisted chemistry procedure
    84588Assay of vasopressin
    Quantitative Troponin Frequency
    Maximum frequencyUp to 4 quantitative cardiac troponin measurements
    Time limitWithin the first 72 hours following initial presentation
    Applicable testingQuantitative troponin T or I for diagnosis of myocardial infarction in individuals presenting with acute coronary syndrome signs or symptoms
    BNP or NT-proBNP Frequency
    Eligible testsB-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP)
    Heart failure diagnosisUsed to diagnose heart failure in individuals presenting with dyspnea

    Provider Billing Actions

    Documentation Required

    Verify product and plan requirements

    Review the applicable plan documents and product-specific requirements before billing. Not all reimbursement requirements apply to every product, and plan documents or provider contracts govern if they conflict with this policy.

    Documentation Required

    Submit accurate coding and documentation

    Submit accurate documentation of the services performed and claims using valid HIPAA-approved code combinations. Code claims according to applicable industry-standard coding guidelines; additional documentation may be requested and claims are subject to claim review.

    • Use valid code combinations from HIPAA-approved code sets.
    • Apply applicable industry-standard coding guidelines, including CPT, HCPCS, ICD-10-CM, ICD-10-PCS, NDC, DRG, NCCI, and other CMS guidelines.
    • Provide additional documentation upon request.

    Clinical and Setting Definitions

    Common Signs and Symptoms
    Chest painIschemic chest pain, including squeezing, tightness, pressure, constriction, crushing, strangling, burning, heartburn, fullness, or a band-like sensation
    Pain radiationPain may radiate to an upper extremity or both arms, upper abdomen, shoulders, arms, wrist, fingers, neck, throat, lower jaw, teeth, or back
    Associated symptomsDiaphoresis, nausea, vomiting, shortness of breath, belching, indigestion, dizziness, lightheadedness, clamminess, or fatigue
    Atypical Signs and Symptoms
    BreathingDyspnea alone
    Gastrointestinal symptomsNausea and/or vomiting or epigastric pain or discomfort
    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure
    Policy CodePolicy RPLAB046
    Change TypeAdministrative/reference updateno reimbursement change
    Effective DateDec 4, 202615d
    Next Review DateN/A
    Key ActionBill quantitative troponin only in an appropriate outpatient facility and no more than four times within the first 72 hours when acute coronary syndrome criteria are met.
    SourceLink
    On This Page
    Cardiac Biomarker Coverage CriteriaCoding and Frequency LimitsProvider Billing ActionsClinical and Setting Definitions
  1. In all outpatient situations, analysis of ST2 and/or its isoforms, including Presage ST2.
  2. Chronic heart failure severityUsed to establish disease severity in individuals with chronic heart failure, up to 4 times per year in the outpatient setting
    Billing Rule

    Bill quantitative troponin within setting and frequency limits

    For individuals presenting with signs or symptoms of acute coronary syndrome, quantitative troponin T or I testing for myocardial infarction may be reimbursable only when performed in an outpatient facility capable of an adequate clinical myocardial infarction evaluation. Limit testing to no more than four times within the first 72 hours after initial presentation.

    • Use quantitative, not qualitative, troponin testing.
    • Bill no more than four measurements within the first 72 hours following initial presentation.
    Billing Rule

    Bill BNP or NT-proBNP for specified indications

    Bill BNP or NT-proBNP when used to diagnose heart failure in an individual presenting with dyspnea or to establish disease severity in an individual with chronic heart failure. For chronic heart failure disease-severity assessment, outpatient testing is limited to four times per year.

    • Qualifying indications: diagnosis of heart failure with dyspnea, or establishment of disease severity in chronic heart failure.
    • Apply the four-times-per-year limit to chronic heart failure testing in the outpatient setting.
    Denial Risk

    Avoid nonreimbursable biomarker claims

    Do not bill nonreimbursable cardiac biomarker testing for the stated circumstances. This includes legacy or alternative biomarkers used for acute coronary syndrome or myocardial infarction evaluation, qualitative outpatient troponin, testing in an outpatient setting unable to perform an adequate clinical myocardial infarction evaluation, and ST2 analysis in any outpatient situation.

    • Do not bill AST/SGOT, CK-MB, CK, creatine kinase isoenzymes, LD/LDH, or myoglobin for MI diagnosis or prognosis in individuals with acute coronary syndrome signs or symptoms.
    • Do not bill copeptin, troponin C, C-reactive protein, H-FABP, or other unlisted cardiac biomarkers for MI diagnosis or prognosis in that setting.
    • Do not bill qualitative troponin T or I in the outpatient setting.
    • Do not bill outpatient cardiac biomarker testing where an adequate clinical MI evaluation cannot be performed.
    • Do not bill ST2 or ST2 isoform analysis in any outpatient situation.
    Other atypical presentationsWeakness, palpitations, syncope, or cardiac arrest
    Adequate Clinical MI Evaluation Setting
    Required settingAn outpatient facility capable of performing an adequate clinical myocardial infarction evaluation
    Applicable testingQuantitative cardiac troponin T or I testing for individuals presenting with acute coronary syndrome signs or symptoms
    Setting limitationTesting in an outpatient setting unable to perform an adequate clinical myocardial infarction evaluation, such as an independent laboratory or physician’s office, is not reimbursable